Israel-based dermatology company Sol-Gel Technologies (NASDAQ: SLGL) and Searchlight Pharma, a Canadian specialty pharmaceutical company, on Tuesday announced exclusive license agreements for the Canadian market for dermatology drugs, TWYNEO and EPSOLAY developed by Sol-Gel.
Sol-Gel will receive up to USD11m in upfront payments, regulatory and sales milestones and royalties for both drugs.
Searchlight Pharma plans to file Canadian regulatory submissions in early 2024 and expects both products to be key parts of its dermatology pipeline.
TWYNEO is used to treat acne vulgaris in adults and paediatric patients, while EPSOLAY is used for inflammatory lesions of rosacea in adults.
Sol-Gel will support Searchlight in obtaining and maintaining regulatory approvals in Canada. Both companies aim to maximize the presence of the drugs in Canada and Sol-Gel has already obtained FDA approval for TWYNEO and EPSOLAY in the US.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval